A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Brief summary (registry, in English)

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 270
• From 17 Apr 2026 to the primary completion date, 3 Sept 2027
• 62 sites in 10 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 75 with type 2 diabetes. It tests different doses of a new medicine, NNC0662-0419, against placebo or semaglutide.

Age

18 to 75 years

Sex

Men and women (sex at birth)

Disease stage

Type 2 diabetes with an HbA1c of 7.0-10.0 percent (53-86 mmol/mol) at screening

Earlier treatment

No medicine for diabetes or obesity in the 90 days before screening. Short insulin treatment for up to 14 days in a row, and earlier insulin for gestational diabetes, is allowed.

Biomarker or test result

HbA1c of 7.0-10.0 percent (53-86 mmol/mol), measured by the central laboratory at screening

Main reasons for not taking part

• Treatment with other diabetes or obesity medicine within 90 days before screening
• Uncontrolled and possibly unstable diabetic retinopathy or maculopathy
• Known hypoglycaemic unawareness

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (62)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details